BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4710. [PMID: 33946835 DOI: 10.3390/ijms22094710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun R, Zhang Z, Bao R, Guo X, Gu Y, Yang W, Wei J, Chen X, Tong L, Meng J, Zhong C, Zhang C, Zhang J, Sun Y, Ling C, Tong X, Yu F, Yu H, Qu W, Zhao B, Guo W, Qian M, Saiyin H, Liu Y, Liu R, Xie C, Liu W, Xiong Y, Guan K, Shi Y, Wang P, Ye D. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Eso Y, Seno H. Optimization of immunotherapy for patients with hepatobiliary cancer. Hepatobiliary Surg Nutr 2021;10:717-9. [PMID: 34760984 DOI: 10.21037/hbsn-21-207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Moeini P, Niedźwiedzka-Rystwej P. Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment. Int J Mol Sci 2021;22:7239. [PMID: 34281293 DOI: 10.3390/ijms22137239] [Cited by in F6Publishing: 4] [Reference Citation Analysis]